Tuesday, November 17, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Eli Lilly Faces Intensifying Competition in Weight-Loss Drug Arena

SiterGedge by SiterGedge
March 26, 2026
in Analysis, Market Commentary, Pharma & Biotech
0
Eli Lilly Stock
0
SHARES
79
VIEWS
Share on FacebookShare on Twitter

The pharmaceutical landscape for weight-loss medications is transforming into a fiercely competitive battleground. Recent clinical advancements from Danish rival Novo Nordisk are prompting investors to reassess the premium valuation of U.S.-based Eli Lilly, a company once considered to hold an almost unassailable lead in its development pipeline.

A Tightening Race in Multi-Receptor Agonists

The catalyst for this renewed scrutiny stems from Novo Nordisk’s recent Phase 2 trial results for its candidate, UBT251. This triple hormone receptor agonist demonstrated a weight loss of 9.8% and an A1C reduction of 2.16% after 24 weeks. This development positions the drug as a direct challenger to Eli Lilly’s own promising contender, Retatrutide.

While Lilly’s drug currently maintains an edge—showing up to 16.8% weight reduction in its 40-week Phase 3 study—market observers interpret the narrowing gap as a clear sign that competition in the multi-receptor agonist segment is escalating significantly. The stakes are substantial, with Retatrutide’s potential peak annual sales estimated at over $30 billion.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Stock Adjustment Reflects Sector Realignment

This heightened competitive pressure has impacted Eli Lilly’s share performance. Since the start of the year, the stock has shed approximately 14% of its value, currently trading at €792.20. Analysts from Seeking Alpha view this pullback as a understandable correction within the broader pharmaceutical sector. Previously elevated valuation multiples have normalized, with the stock now trading at roughly 27 times expected 2026 earnings. This level presents a more balanced risk-reward profile for investors.

Fundamentally, the company’s foundation remains robust. Following a revenue surge to $65.2 billion last year, management has set ambitious targets for the 2026 fiscal year:

  • Total Revenue: $80 to $83 billion
  • Earnings Per Share (EPS): $33.50 to $35.00
  • Mounjaro Revenue: Forecast at $22.8 billion
  • Zepbound Revenue: Estimated at $18.1 billion

Pivotal FDA Decision on the Horizon

A major near-term catalyst for the stock is scheduled for April 2026. The U.S. Food and Drug Administration (FDA) is set to rule on the approval of Orforglipron, an oral GLP-1 receptor agonist. In preparation for a potential green light, Eli Lilly has proactively built inventory worth $1.5 billion to ensure immediate supply. A favorable decision would grant the company direct access to patients who prefer oral tablets over injections, further solidifying its market position against Novo Nordisk.

Ad

Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from November 17 delivers the answer:

The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 17.

Eli Lilly: Buy or sell? Read more here...

Tags: Eli Lilly
SiterGedge

SiterGedge

Related Posts

Shell Stock
Commodities

Shell’s Gas Ambitions Meet Buyback Discipline as LNG Canada Talks Take Shape

September 25, 2026
SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Next Post
Adobe Stock

Adobe's Stock Paradox: Record Results Meet Investor Skepticism

Intel Stock

Intel's Strategic Hardware Expansion Fuels Market Confidence

AMD Stock

AMD Stock Soars on Pricing Strength and AI Momentum

Recommended

Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals: A Pivotal Year of Clinical Catalysts and Financial Milestones

8 months ago
Marvell Technology Stock

Marvell Technology’s AI Business Fuels Record Quarter Amid Mixed Segment Performance

1 year ago
Ondas Holdings Stock

Ondas Holdings: Can New Contracts Reignite Its Stalled Momentum?

12 months ago
Block Stock

A Tale of Two Titans: Block and PayPal’s Divergent Fintech Paths

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Four Down Weeks for the Nasdaq, and Consumer Stocks Quietly Cash In

Trending

Home Depot Stock
Newsletter

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

by Stephanie Dugan
November 17, 2026
0

Dear readers, Home Depot did what it was supposed to do on Tuesday morning and got little...

Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026
Cisco Stock

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

November 12, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went
  • At 5.15%, the 10-Year Treasury Picks the Winners

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com